Newsfeeds - Spark Newswire

1 minute read

Arcutis Stops ARQ-252 Vitiligo Trial After Formulation-Related Observations In Chronic Hand Eczema Study

Today, 2:45 PM

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) will terminate the Phase 2a trial evaluating ARQ-252 as a potential treatment for vitiligo. The study was initiated…

ARQT

10 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For June 30, 2021

By Benzinga Insights

Today, 2:45 PM

Upgrades

AJX

1 minute read

Mizuho Initiates Coverage On Arcutis Biotherapeutics with Buy Rating, Announces Price Target of $58

By Benzinga Newsdesk

Today, 2:45 PM

Mizuho initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy rating and announces Price Target of $58.

ARQT

1 minute read

Uncategorized

Morgan Stanley Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $52

By Benzinga Newsdesk

Today, 2:45 PM

Morgan Stanley analyst David Lebowitz initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight rating and announces Price Target of $52.

ARQT

5 minute read

Uncategorized

Arcutis Biotherapeutics Says Showcasing Pivotal DERMIS-1 And-2 Phase 3 Trial Data For Topical Roflumilast Cream (ARQ-151) In Plaque Psoriasis At EADV Spring Symposium 2021; Shares Up 7%

By Benzinga Newsdesk

Today, 2:45 PM

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and

ARQT

4 minute read

Uncategorized

55 Biggest Movers From Friday

By Lisa Levin

Today, 2:45 PM

Gainers

AHT

Latest news

Arcutis Stops ARQ-252 Vitiligo Trial After Formulation-Related Observations In Chronic Hand Eczema Study

Benzinga’s Top Ratings Upgrades, Downgrades For June 30, 2021

Mizuho Initiates Coverage On Arcutis Biotherapeutics with Buy Rating, Announces Price Target of $58

Morgan Stanley Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $52

Arcutis Biotherapeutics Says Showcasing Pivotal DERMIS-1 And-2 Phase 3 Trial Data For Topical Roflumilast Cream (ARQ-151) In Plaque Psoriasis At EADV Spring Symposium 2021; Shares Up 7%

55 Biggest Movers From Friday